Publication Cover
Redox Report
Communications in Free Radical Research
Volume 16, 2011 - Issue 1
708
Views
24
CrossRef citations to date
0
Altmetric
Correspondence

Evaluation of oxidative stress status in children with pervasive developmental disorder and attention deficit hyperactivity disorder using urinary-specific biomarkers

, &
Pages 45-46 | Published online: 19 Jul 2013

Abstract

Pervasive developmental disorder (PDD) and attention deficit hyperactivity disorder (ADHD) are likely to be associated with increased oxidative stress, particularly that of lipid peroxidation. We evaluated the oxidative stress status of pediatric PDD and ADHD patients using their urine samples. Urinary acrolein-lysine levels in 11 PDD and 10 ADHD children (205 ± 97 and 234 ± 75 nmol/mg Cr, respectively) appeared higher than those of the control subjects (155 ± 59 nmol/mg Cr). Measurement of urinary specific biomarkers is comfortable, non-invasive, and easy to perform in children. Our findings might provide a scientific guide for use in further clinical and biochemical studies of these disorders.

Pervasive developmental disorder (PDD) and attention deficit hyperactivity disorder (ADHD) are likely to be associated with increased oxidative stress, particularly that of lipid peroxidation.Citation1Citation3 We evaluated the oxidative stress status of pediatric PDD and ADHD patients using their urine samples.

The patients were 11 PDD children (M/F = 9/2; mean ± SD = 11 ± 4 years) and 10 ADHD children (M/F = 6/4; 10 ± 3 years) for whom diagnoses were made according to DSM-IV criteria. Seventy-three children served as healthy age-matched controls (M/F = 34/39; 10 ± 4 years). As the urinary biomarker, acrolein-lysine was measured, reflecting the amount of lipid peroxidation in vivo.Citation4 Our institutional medical ethics committee approved the project; informed consent was obtained from their parents.

Urinary acrolein-lysine levels in PDD and ADHD children (205 ± 97 and 234 ± 75 nmol/mg Cr, respectively) appeared higher than those of the control subjects (155 ± 59 nmol/mg Cr). The difference between the ADHD and control groups was statistically significant (P < 0.05 using Student's t-test). Patients showing considerably high levels (defined as > +2SD value in the controls) were four (36%) and three (30%), respectively, in the PDD and ADHD groups.

Cauhan et al.Citation1 reported that plasma malondialdehyde, another biomarker of lipid peroxidation, was significantly higher in autistic children than in their non-autistic siblings. Ming et al.Citation2 reported that autism was related to increased oxidative stress as evaluated with urinary 8-hydroxy-2-deoxyguanosine and 8-isoprostane-F2α. Also, Bulut et al.Citation3 reported that the plasma malondialdehyde in ADHD adults was significantly higher than the control level. Our results show that urinary acrolein-lysine is significantly elevated in ADHD children and that about 30% of the patients with PDD and ADHD have markedly high levels. The exact mechanism of increased oxidative stress, particularly that of lipid peroxidation in these patients remains to be clarified. It might be genetic, environmental, or both.

Measurement of urinary-specific biomarkers is comfortable, non-invasive, and easy to perform in children. Our findings might provide a scientific guide for use in further clinical and biochemical studies of these disorders.

References

  • Cauhan A, Cauhan V, Brown WT, Cohen I. Oxidative stress in autism: increased lipid peroxydation and reduced serum levels of ceruloplasmin and transferrin – the antioxidant proteins. Life Sci 2004;75:2539–49.
  • Ming X, Stein TP, Brimacombe M, Johnson WG, Lambert GH, Wagner GC. Increased excretion of a lipid peroxidation biomarker in autism. Prostaglandins Leukot Essent Fatty Acids 2005;73:379–84.
  • Bulut M, Selek S, Gergerlioglu S, Savas HA, Yilmaz HR, Yuce M, et al. Malondialdehyde levels in adult attention-deficit hyperactivity disorder. J Psychiatry Neurosci 2007;32:435–8.
  • Tsukahara H. Biomarkers for oxidative stress: clinical application in pediatric medicine. Curr Med Chem 2007;14:339–51.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.